– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 –
Read more at globenewswire.com
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire - Last update: May 14, 2025
Article Mentions:
